Cargando…

Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis

Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du Pasquier, Renaud A., Pinschewer, Daniel D., Merkler, Doron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057629/ https://www.ncbi.nlm.nih.gov/pubmed/24723124 http://dx.doi.org/10.1007/s40263-014-0160-8

Ejemplares similares

The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
por: Sahin, Mehmet, et al.
Publicado: (2021)

Multiple sclerosis: Possible immunological mechanisms()
por: McFarland, Henry F., et al.
Publicado: (1989)

Envelope Exchange for the Generation of Live-Attenuated Arenavirus Vaccines
por: Bergthaler, Andreas, et al.
Publicado: (2006)

Persistent RNA virus infection is short-lived at the single-cell level but leaves transcriptomic footprints
por: Reuther, Peter, et al.
Publicado: (2021)

Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations
por: Dooley, James, et al.
Publicado: (2016)

Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients
por: Lalive, Patrice H., et al.
Publicado: (2017)

Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV
por: Di Liberto, Giovanni, et al.
Publicado: (2022)

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
por: Pardo, Gabriel, et al.
Publicado: (2017)

Remodeling of Axonal Connections Contributes to Recovery in an Animal Model of Multiple Sclerosis
por: Kerschensteiner, Martin, et al.
Publicado: (2004)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection
por: Steinbach, Karin, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Capillaroscopy and Immunological Profile in Systemic Sclerosis
por: Lambova, Sevdalina Nikolova, et al.
Publicado: (2022)

Immunology and Oxidative Stress in Multiple Sclerosis: Clinical and Basic Approach
por: Ortiz, Genaro G., et al.
Publicado: (2013)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes
por: Perriard, Guillaume, et al.
Publicado: (2015)

Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotropic Hormone
por: Ross, Amy Perrin, et al.
Publicado: (2013)

Immunological role of sulfatide in the pathogenesis of multiple sclerosis
por: Hamatani, Mio, et al.
Publicado: (2023)

Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination
por: Rodriguez, Enrique Garea, et al.
Publicado: (2014)

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
por: de Flon, Pierre, et al.
Publicado: (2018)

Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis
por: ELBini-Dhouib, Ines, et al.
Publicado: (2022)

Multiple Sclerosis Decreases Explicit Counterfactual Processing and Risk Taking in Decision Making
por: Simioni, Samanta, et al.
Publicado: (2012)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study
por: Tortorella, Paola, et al.
Publicado: (2014)

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
por: Gerdes, Lisa Ann, et al.
Publicado: (2016)

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis
por: Arnason, Barry G, et al.
Publicado: (2013)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis
por: Eshaghi, Arman, et al.
Publicado: (2019)

Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action
por: Muñoz-Jurado, Ana, et al.
Publicado: (2022)

Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
por: Witman Tsur, Shani, et al.
Publicado: (2021)

20680 Characterization of Clinical and Immunological Laboratory Features in Multiple Sclerosis Patients with COVID-19
por: Ali, Ahya S, et al.
Publicado: (2021)

Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
por: Morris, Aaron H., et al.
Publicado: (2020)

Types of immunological failure in the "slow-virus" encephalopathies and multiple sclerosis.
por: Booss, J.
Publicado: (1980)

Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes
por: Todea, Ramona-Alexandra, et al.
Publicado: (2020)

The Multiple Sclerosis Prodrome: Evidence to Action
por: Tremlett, Helen, et al.
Publicado: (2022)

Pembrolizumab as a treatment for PML?: Waiting for Godot
por: Du Pasquier, Renaud A.
Publicado: (2019)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
por: Morillo Verdugo, Ramón, et al.
Publicado: (2019)

The MoxFo initiative—Mechanisms of action: Biomarkers in multiple sclerosis exercise studies
por: Rosenkranz, Sina C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n9cvtpcsqqvralfddrp062ko2s